These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355 [TBL] [Abstract][Full Text] [Related]
4. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. Lee JH; Kim Y; Choi JW; Kim YS J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537 [TBL] [Abstract][Full Text] [Related]
6. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib]. Hong JL; Li J; Li J; Shen L Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406 [TBL] [Abstract][Full Text] [Related]
7. Molecular research directions in the management of gastrointestinal stromal tumors. Tarn C; Godwin AK Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052 [TBL] [Abstract][Full Text] [Related]
8. C-kit, GIST, and imatinib. Siehl J; Thiel E Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922 [TBL] [Abstract][Full Text] [Related]
9. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971 [TBL] [Abstract][Full Text] [Related]
10. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Heinrich MC; Owzar K; Corless CL; Hollis D; Borden EC; Fletcher CD; Ryan CW; von Mehren M; Blanke CD; Rankin C; Benjamin RS; Bramwell VH; Demetri GD; Bertagnolli MM; Fletcher JA J Clin Oncol; 2008 Nov; 26(33):5360-7. PubMed ID: 18955451 [TBL] [Abstract][Full Text] [Related]
11. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene. Yamaguchi M; Matsumoto T; Tate G; Higuchi T J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413 [No Abstract] [Full Text] [Related]
12. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Gounder MM; Maki RG Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624 [TBL] [Abstract][Full Text] [Related]
13. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
14. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769 [TBL] [Abstract][Full Text] [Related]
15. [GIST refractory to imatinib treatment]. Onozawa Y; Terashima M Gan To Kagaku Ryoho; 2011 May; 38(5):738-43. PubMed ID: 21566433 [TBL] [Abstract][Full Text] [Related]
16. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors. Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465 [TBL] [Abstract][Full Text] [Related]
17. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment. Koyama T; Nimura H; Kobayashi K; Marushima H; Odaira H; Kashimura H; Mitsumori N; Yanaga K Gastric Cancer; 2006; 9(3):235-9. PubMed ID: 16952044 [TBL] [Abstract][Full Text] [Related]
18. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment. Yeh CN; Chen TW; Liu FY; Jan YY; Chen MF Langenbecks Arch Surg; 2006 Nov; 391(6):615-21. PubMed ID: 17024483 [TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors. Wang CM; Huang K; Zhou Y; Du CY; Ye YW; Fu H; Zhou XY; Shi YQ J Cancer Res Clin Oncol; 2010 Jul; 136(7):1065-71. PubMed ID: 20043176 [TBL] [Abstract][Full Text] [Related]
20. Establishment of the prediction model and biological mechanism exploration for secondary imatinib-resistant in gastrointestinal stromal tumor. Wang C; Shen Z; Jiang K; Gao Z; Ye Y Scand J Gastroenterol; 2022 Nov; 57(11):1334-1343. PubMed ID: 35723035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]